OSSD Share Price Performance
SEK 10.90
2.50 (29.76%)
29.7% undervalued intrinsic discount
SEK 15.50
Fair Value
Price SEK 10.90
AnalystConsensusTarget SEK 15.50
AnalystLowTarget SEK 12.00
Fair ValueSEK 15.50
Share Pricen/a
OssDsign AB (publ) Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 6 Fair Values set on narratives written by author
OSSD Community Narratives
AN
Fair Value SEK 15.5 29.7% undervalued intrinsic discount
Pure Play Orthobiologics Will Expand US Healthcare Access
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
Fair Value SEK 12 9.2% undervalued intrinsic discount
Rising US Healthcare Cost Controls Will Squeeze Orthobiologics Margins
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Rising US Healthcare Cost Controls Will Squeeze Orthobiologics Margins
Key Takeaways Intensifying pricing pressures and consolidated buyer power threaten margins and profitability, as healthcare cost controls and hospital alliances focus on affordability over innovation. High operating expenses from R&D and limited product diversification expose the company to disruptive competition, slow commercial progress, and volatile earnings.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
SEK 12
9.2% undervalued intrinsic discount
AnalystLowTarget Fair Value
Revenue growth
28.07% p.a.
Profit Margin
10.19%
Future PE
52.88x
Share price in 2028
SEK 12.49
Pure Play Orthobiologics Will Expand US Healthcare Access
Key Takeaways Strategic shift to orthobiologics boosts growth and operational efficiency, enhancing future revenue and sustaining high net margins. U.S. market expansion and distinctive product benefits position OssDsign for significant market share and increased adoption.Read more
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
SEK 15.5
29.7% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
29.4% p.a.
Profit Margin
0.15%
Future PE
3.95kx
Share price in 2028
SEK 20.54
Snowflake Analysis
OssDsign AB (publ) Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
Feb 10, 2026
- -0.38
- 96.40%
- -23.66%
- 0%
About OSSD
- Founded
- 2011
- Employees
- 32
- CEO
- WebsiteView website
OssDsign AB (publ) designs, manufactures, and sells implants and material technology for bone regeneration in Sweden, Germany, the United States, the United Kingdom, rest of Europe, and internationally. It offers OssDsign Catalyst, a nanosynthetic bone graft for dual bone formation pathways through fusion mass. The company was founded in 2011 and is headquartered in Uppsala, Sweden.
